Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Merck Profits Soar in Q3

October 28, 2011 6:39 am | by Linda A. Johnson | News | Comments

Drugmaker Merck & Co. said that its third-quarter profit soared from results a year ago that were weighed down by huge acquisition and legal charges.

TOPICS:

Method for Estimating Vaccine Coverage Developed

October 27, 2011 12:36 pm | News | Comments

According to a study led by researchers from the Johns Hopkins Bloomberg School of Public Health, estimates of vaccination coverage can be improved by combining administrative data with survey data.

TOPICS:

Cell Therapeutics Resubmits Pixantrone to FDA

October 27, 2011 12:33 pm | News | Comments

Cell Therapeutics Inc. resubmitted the pixantrone New Drug Application to the U.S. Food and Drug Administration's Division of Oncology Drug Products for accelerated approval to treat relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed prior therapy.

TOPICS:
Advertisement

BMS, Gilead Sciences Combine on HIV Pill

October 27, 2011 12:30 pm | News | Comments

Bristol-Myers Squibb and Gilead Sciences announced a licensing agreement for Bristol-Myers Squibb to develop and commercialize a fixed-dose combination containing its protease inhibitor Reyataz and Gilead’s cobicistat.

TOPICS:

Despite DNA Differences, Human Brains All the Same

October 27, 2011 12:26 pm | News | Comments

Despite vast differences in the genetic code across individuals and ethnicities, the human brain shows a “consistent molecular architecture,” say researchers supported by the National Institutes of Health.

TOPICS:

Xoma, Aragen Enter Antiobody Agreement

October 27, 2011 12:20 pm | News | Comments

Xoma Ltd. and Aragen Bioscience Inc. entered into an agreement under which Aragen Bioscience will provide its clients access to Xoma’s human engineering technology for antibody humanization.

TOPICS:

Emerald BioStructures, UCB Extend Collaboration

October 27, 2011 12:16 pm | News | Comments

Emerald BioStructures announced a three-year extension of its ongoing collaboration with UCB.

TOPICS:

Almac Invests $1.4 Million in Laboratory

October 27, 2011 12:12 pm | News | Comments

Almac has established a mass spectrometry laboratory in their European Headquarters, Craigavon, United Kingdom.

TOPICS:
Advertisement

Digital Thermometer

October 27, 2011 8:15 am | Product Releases | Comments

Control Company’s Traceable digital hygrometer/thermometer/dew point instrument provides a response time of under 10 seconds with a resolution of 0.01% RH, 0.01°F/°C, and 0.01° dew point °F/°C.

TOPICS:

Water Purification Unit

October 27, 2011 8:10 am | Product Releases | Comments

The arium pro from Sartorius Stedim Biotech provides ultrapure water for analytical applications like atomic absorption, ion exchange chromatography and inductively coupled plasma mass spectrometry.

TOPICS:

Boehringer Buys Hamilton System for Research Center

October 27, 2011 7:53 am | News | Comments

Hamilton Storage Technologies and Robotics have delivered and successfully installed an integrated compound management system at Boehringer Ingelheim's Research and Development Centre.

TOPICS:

Activartis in Phase 2 Trial of Cancer Therapy

October 27, 2011 7:45 am | News | Comments

Activartis GmbH is developing a cancer immunotherapy concept which is currently in Phase 2 clinical trials. The Activartis platform focuses on dendritic cells, the key regulatory elements of the immune system.

TOPICS:

Victoza Boosts Novo Nordisk Profits

October 27, 2011 7:39 am | News | Comments

Danish pharmaceutical company Novo Nordisk A/S says its net profit grew by 17% in the third quarter, chiefly spurred by strong sales of its new diabetes drugs.

TOPICS:

EU Expands Prevnar Approval

October 27, 2011 7:35 am | News | Comments

Pfizer Inc.'s blockbuster vaccine against dangerous bacterial infections has been approved in Europe for use in adults age 50 and older, the drugmaker announced.

TOPICS:

AstraZeneca Profits Drop 2%

October 27, 2011 7:32 am | News | Comments

Drug maker AstraZeneca says underlying profit was down 2% in the third quarter but net profit more than doubled because of the sale of a subsidiary.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading